HD-OPM Archive

CT angiography (CCTA): seeing soft plaque

A coronary CT angiogram can show soft, non-calcified plaque that a calcium score cannot see, and it lets researchers measure plaque in cubic millimetres over time. This summary explains what CCTA adds beyond CAC, what SCOT-HEART showed, what plaque-tracking trials have found, and where the test falls short.

16 min read45 group posts cited37 studies discussed4 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • A calcium (CAC) scan sees only calcified plaque; CCTA also images soft, non-calcified plaque, which the group's admins regard as the dangerous kind. In one Danish registry of 23,759 symptomatic patients, 54% had a CAC of zero.
  • In SCOT-HEART (4,146 patients with stable chest pain), adding CCTA to standard care was followed by coronary death or nonfatal heart attack in 2.3% versus 3.9% at five years, mainly because more people with plaque were started on aspirin and statins.
  • A typical at-risk person grows roughly 5 mm3 of non-calcified plaque a year; in DISCO-CT a DASH diet plus statins reduced it by about 40 mm3 (adjusted to one year), and in FLOWPROMOTE LDL near 42 mg/dL cut total plaque volume by about 21% in 18 months.
  • Results depend on the software and the scanner: the same Keto-CTA scans gave a median soft-plaque rise of 18.8 mm3 with one program and about 5.5 mm3 with two others, and the original paper was retracted.
  • CCTA costs more than CAC and uses more radiation, and a normal scan does not exclude early wall plaque; the admins suggest discussing with your doctor whether and when to scan.
In this summary
  1. What CCTA shows that a calcium score does not
  2. How plaque is measured on CCTA
  3. SCOT-HEART: what it found
  4. What plaque-tracking trials have found
  5. Limits and controversies
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

A coronary CT angiogram (CCTA) is a heart CT scan done with injected contrast dye. Unlike a calcium score scan, which only picks up calcium, CCTA outlines the inside of the coronary arteries and the plaque in their walls, including the soft, lipid-rich plaque that does not contain calcium. A calcium score tells you plaque is definitely there but not the whole picture, whereas AI-assisted plaque analysis of a CCTA can describe how much plaque there is, where it sits and what type it is1.

Group admins Louis Nervegna and Gokhan Can return to CCTA often because it is the tool behind most of the plaque-tracking trials the group discusses. It is also the test that SCOT-HEART, a large randomized trial, tied to fewer heart attacks in people with chest pain2. The scan is not perfect, though. It costs more, involves more radiation than a calcium scan, and the numbers it produces depend on the software that reads them.

This summary walks through what CCTA shows beyond CAC, what SCOT-HEART found, what the plaque-tracking studies say, and who the group's posts suggest might consider one. None of this is personal medical advice; the group's admins consistently suggest discussing imaging decisions with your own doctor.

54%of 23,759 symptomatic Danish patients had a calcium score of zero on CT angiography34
2.3% vs 3.9%coronary death or heart attack over five years with CCTA versus standard care in SCOT-HEART2
About 5 mm³of soft plaque added each year by a typical at-risk person on a Western diet56
18.8 vs 5.5 mm³median soft-plaque rise for the same Keto-CTA scans read by two different programs57

What CCTA shows that a calcium score does not

Soft plaque versus calcified plaque

Louis describes calcified plaque (what a CAC score measures) as the stable, older material and non-calcified, especially low-density soft plaque, as what ruptures and causes heart attacks1. He argues that a high CAC predicts risk mainly because calcified plaque is a proxy for the amount of soft plaque that came before it9. A staging explainer shared by Gokhan describes coronary disease as beginning with soft plaque, sometimes in childhood or young adulthood, with calcification showing up later and symptoms later still10. Louis adds that by the time calcium appears, a person has probably had soft plaque for years, maybe decades3.

A related point comes from the PARADIGM imaging analysis quoted in the group: low-attenuation plaque (a dark, fatty type of soft plaque on CT) strongly predicts future events such as heart attack, and in SCOT-HEART it predicted events better than a risk score, CAC or the presence of obstructive disease. Very dense calcified plaque, by contrast, was associated with a lower risk of acute coronary syndrome11.

Why a zero calcium score is not a clean bill of health

Because soft plaque has no calcium, CAC can miss it. The group has repeatedly pointed to the Western Denmark Heart Registry: of 23,759 consecutive symptomatic patients (median age 58, 55% women) who had CT angiography, 54% had a CAC of zero, and half of the people with obstructive blockages had a zero score34. Louis's summary of this is that CAC shows late-stage disease and is a poor tool for early detection3.

The NEJM REACT study, shared in the group, studied 16,808 adults aged 18 to 70 without known disease using vascular ultrasound plus coronary CT angiography. Plaque was present in 57% overall. Among 30 to 39 year olds who had plaque on CT angiography, 41.8% of men and 48.4% of women had a calcium score of zero, because early plaques may be non-calcified and invisible to calcium scoring12. Louis summarizes the study as showing that age is the biggest risk factor; roughly 1 in 13 people in their 20s had plaque, rising to about 9 in 10 in their 60s, with men developing silent disease about 5 to 10 years earlier than women13. It is a cross-sectional study, meaning it counted plaque at a single point in time rather than following people over years13.

How plaque is measured on CCTA

Plaque studies use a few recurring terms.

  • TAV (total atheroma volume) is the overall plaque volume, soft and calcified together. PAV (percent atheroma volume) expresses it as a share of the vessel volume14.
  • NCPV (non-calcified plaque volume) is the soft plaque alone. NCPV is reported in mm3 or in microlitres (uL); one mm3 is exactly one uL, which matters when comparing studies15.
  • Low-attenuation plaque is the fattiest, highest-risk subset of soft plaque11.

Software does the measuring. The group mentions Cleerly, HeartFlow and QAngio, and the American College of Cardiology guidance on AI-based quantitative coronary plaque analysis (QCPA) that Louis shared. According to the summary posted, the guidance supports QCPA for people who already have plaque on their scan, to help make treatment decisions and follow the response, with rescans at intervals of at least two to five years1.

Louis also quotes a review arguing that, in large contemporary cohorts, total plaque burden and non-calcified plaque volume often outperform stenosis (how narrow the artery is) as predictors of future events16. He predicts that as cost and radiation fall, CCTA will become standard in preventive cardiology, though he presents that as his expectation rather than current practice16.

One extension is the CaRi-Heart analysis, which uses AI on a standard CT angiogram to estimate coronary inflammation through the fat attenuation index (FAI). A member shared a case in which stenosis fell from 70% to under 25% after LDL was lowered to 35-50 mg/dL, yet the FAI score was high (8.1, 93rd percentile) despite an hs-CRP of 0.15 mg/L. Louis's view is that this is probably the most accurate non-invasive way to measure residual inflammatory risk and that no blood test captures it; that is his opinion, not an established standard17.

SCOT-HEART: what it found

SCOT-HEART followed 4,146 patients with stable chest pain for five years. Everyone received standard care, and half also had a coronary CT angiogram. Coronary death or nonfatal heart attack occurred in 2.3% of the CTA group versus 3.9% of the standard-care group, a 41% lower risk, and the benefit was consistent in people with "atypical" symptoms and "possible" angina2.

SCOT-HEART: cumulative rate of coronary death or nonfatal heart attack over five years in 4,146 patients with stable chest pain; the curves separate after the first months, with fewer events in the CTA group than with standard care alone.
SCOT-HEART: cumulative rate of coronary death or nonfatal heart attack over five years in 4,146 patients with stable chest pain; the curves separate after the first months, with fewer events in the CTA group than with standard care alone.2

Gokhan's summary of a follow-up analysis (JACC, 2019) explains why. The scan did not heal anything on its own. It showed who actually had plaque, so more of those patients were started on aspirin and statins, and people with no disease could safely avoid unnecessary medication2. The CTA group had slightly more procedures such as stents or bypass surgery in the first year and fewer later, with roughly equal totals by year five2.

The caveats Gokhan lists are important. Participants were people with chest pain, so the findings do not automatically apply to everyone, and the downsides include cost and radiation2.

What plaque-tracking trials have found

CCTA made it possible to measure soft plaque change over a year or so. Louis often benchmarks results against a typical at-risk person, who following a standard Western diet grows about 5 mm3 of non-calcified plaque a year; the Nature-CT analysis of healthy individuals with no statins put the median at 4.9 mm356. In the group's framing, anything much below zero is regression.

Statins and other lipid-lowering drugs

  • Six statin trials (COSMOS, SATURN, ASTEROID, IBIS-4, STABLE, JAPAN-ACS), measured by CCTA or IVUS (intravascular ultrasound, a catheter-based ultrasound), showed total plaque volume falling by about 5% to 17%. Louis notes the falls came from soft plaque, not calcified plaque1819. A chart from a 2022 JACC review suggests regression begins once LDL-C falls below roughly 90 mg/dL, with JAPAN-ACS (atorvastatin 20 mg or pitavastatin 4 mg in acute coronary syndrome) the best result at 17%14.
  • FLOWPROMOTE (JAMA Cardiology, 2026) randomized 104 statin-naive patients with coronary disease to atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg, with CCTA at baseline, 9 and 18 months. LDL fell to 42.5 versus 69.5 mg/dL; total plaque volume fell 21.1% versus 13.6% and soft plaque 28.2% versus 20.0%. Calcified plaque rose in both groups, which the shared write-ups describe as soft plaque hardening and stabilizing2021. The trial measured imaging, not heart attacks20.
  • Evolocumab (Repatha) was studied in 47 patients (mean age 61.8, 87% male) over 18 months with LDL around 30 mg/dL. Soft plaque fell from 607.3 to 562.1 uL and low-attenuation plaque from 37.1 to 20.4 uL, while calcified plaque rose from 108.9 to 148.7 uL, so total plaque was essentially unchanged (716.2 to 710.8 uL). Thirty-seven of 47 patients had some soft-plaque reduction15. Louis stresses there was no randomization or control group, and that PCSK9 inhibitors as monotherapy have not been proven to reduce heart attacks22.
  • A comparison of progression rates, quoted from Dr Brad Stanfield, reports that in the SMARTool cohort high-risk people not on statins gained about 6.4 mm3 of soft plaque per year versus about 1.0 mm3 per year for those on statins23.
FLOWPROMOTE: lower LDL, more plaque shrinkageChange in plaque volume on CT angiography over 18 months, 104 statin-naive patients with coronary disease
Rosuvastatin 40 mg + ezetimibeAtorvastatin 40 mg
Total plaque volume-21.1%-13.6%
Soft (non-calcified) plaque-28.2%-20.0%
LDL fell to 42.5 versus 69.5 mg/dL. Calcified plaque rose in both groups. The trial measured imaging, not heart attacks. Source: 2021
Show data
Rosuvastatin 40 mg + ezetimibeAtorvastatin 40 mg
Total plaque volume-21.1%-13.6%
Soft (non-calcified) plaque-28.2%-20.0%
Evolocumab: soft plaque fell, calcified plaque rosePlaque volume (µL) before and after 18 months of evolocumab with LDL around 30 mg/dL, 47 patients
Baseline18 months
Soft (non-calcified) plaque607.3562.1
Low-attenuation plaque37.120.4
Calcified plaque108.9148.7
Total plaque716.2710.8
No randomization or control group. Total plaque was essentially unchanged because calcified plaque grew as soft plaque shrank. Source: 1522
Show data
Baseline18 months
Soft (non-calcified) plaque607.3562.1
Low-attenuation plaque37.120.4
Calcified plaque108.9148.7
Total plaque716.2710.8
The chart from a 2022 JACC review: change in total plaque volume against achieved LDL-C (mmol/L) across statin, ezetimibe and PCSK9 inhibitor imaging trials; most trials with lower LDL-C show plaque shrinking, with JAPAN-ACS lowest at about −17%.
The chart from a 2022 JACC review: change in total plaque volume against achieved LDL-C (mmol/L) across statin, ezetimibe and PCSK9 inhibitor imaging trials; most trials with lower LDL-C show plaque shrinking, with JAPAN-ACS lowest at about −17%.14

Diet and lifestyle

DISCO-CT randomized 92 non-diabetic people with non-obstructive coronary disease (91 completed) to a dietitian-guided DASH-style diet plus more exercise, or to usual care; everyone was on intensive medical therapy including statins. Soft plaque fell by 51.3 mm3 with the DASH diet versus 21.3 mm3 in the control group. Louis calculates that is 2.4 times more reversal, and adjusts the diet result to 39.5 mm3 per year because the trial ran 66 weeks. In his words this is the largest dietary soft-plaque regression on CT to date, equal to about 8 years of typical progression6. He adds an explicit caveat: the benchmark is a typical American, not these patients' own history6. Calcified plaque did not increase in either DISCO-CT group6. The DASH diet used was about 30% fat, mostly unsaturated24.

Soft plaque usually grows a little each year; diet plus statins reversed itChange in non-calcified plaque volume per year (mm³) in different cohorts and trials cited in the group
High-risk, not on statins (SMARTool)about +6.4
Healthy, no statins (Nature-CT, median)+4.9
High-risk, on statins (SMARTool)about +1.0
DASH diet plus statins (DISCO-CT)−39.5
Different cohorts, scanners and methods, so a rough benchmark only. The DISCO-CT figure is Louis's adjustment of a 66-week result to one year. Source: 5623
Show data
mm³ per year
High-risk, not on statins (SMARTool)about +6.4
Healthy, no statins (Nature-CT, median)+4.9
High-risk, on statins (SMARTool)about +1.0
DASH diet plus statins (DISCO-CT)−39.5

Other agents measured with CCTA

  • Colchicine 0.5 mg daily reduced percent atheroma volume by over 1% in one year in a Budoff-led CCTA trial, with lower CRP and slower calcified plaque progression. Budoff described it as a relatively small study25.
  • Aged garlic extract was reported in a small randomized trial using serial CCTA to slow plaque growth and reduce low-attenuation plaque26.
  • Testosterone went the other way. In a 2017 randomized trial of 170 men aged 65 or older with low testosterone, the testosterone group had an estimated 41 mm3 greater increase in soft plaque than placebo after a year (95% CI 14 to 67). Louis notes that the later TRAVERSE trial found no increase in heart attacks or strokes when treating diagnosed hypogonadism, but only over about 22 months27.
  • Olezarsen lowered triglycerides about 64% and ApoB about 16%, yet 12-month CCTA showed no difference in soft, low-attenuation or total plaque (primary endpoint p=0.36). Louis reads this as showing that lowering triglycerides alone does not slow plaque; the shared write-up itself flagged methodological limits such as short follow-up and near-universal background therapy28.
  • High-dose EPA: a member reported a CCTA-documented regression of a 70% stenosis soft plaque after six months on 6 g/day, without a statin. Louis presented it as a single case and warned that very high fish-oil doses can raise AFib risk29.

Limits and controversies

The lumen "blind spot" and the Glagov effect

Louis has said that CT angiography is a form of "lumenography": dye fills the lumen (the channel where blood flows), so early plaque inside the artery wall is mostly invisible until it narrows the lumen, and a perfect-looking CCTA can coexist with early wall plaque830. Elsewhere in the group, he describes modern high-resolution CT angiography as directly measuring plaque in the wall, soft and hard, long before it narrows the lumen, in contrast to old x-ray angiography3132. These posts are best read together: CCTA sees far more than x-ray angiography, yet early disease can still escape it.

The same logic explains why the older x-ray angiography in the small 1986-1992 Ornish trial is criticized. Early plaque makes arteries expand outward (the Glagov phenomenon), keeping the lumen looking normal32. Louis points out that the lumen changes reported there, 2.1% at one year and 3.4% at five, are below what standard x-ray angiography can reliably resolve31.

The Glagov effect: as plaque builds up, the artery wall expands outward so the channel stays 3.5 mm wide, which is why a lumen-based picture can look normal despite a large plaque burden.
The Glagov effect: as plaque builds up, the artery wall expands outward so the channel stays 3.5 mm wide, which is why a lumen-based picture can look normal despite a large plaque burden.32

Software and the Keto-CTA controversy

The Keto-CTA study followed lean people with very high LDL (about 237 to 254 mg/dL depending on the post) on ketogenic diets, using CCTA and Cleerly software. Louis compared it with Nature-CT, from the same institute, scanners and software, with a mean age near 55, no diabetes and no lipid drugs. Median soft-plaque progression was 18.8 mm3 in Keto-CTA versus 4.9 mm3 in Nature-CT, or 3.8 times faster533.

Several critics noted that the preregistered primary outcome (NCPV) was missing from the paper343536. The original paper was then retracted over concerns about the Cleerly analysis, and the 200 scans were re-analyzed. HeartFlow gave a median rise of 5.5 mm3 and QAngio 5.6 mm37. Louis argues this is still no better than the standard-diet group and that both studies would need re-analysis with the same software for a fair comparison3738. His view is that of an admin; the lesson that applies to everyone is that absolute CCTA plaque numbers can shift with the analysis program. A statistician's independent reanalysis of the released data also alleged statistical problems, to which the authors had not yet responded39.

Same scans, three programs, very different answersMedian rise in soft (non-calcified) plaque in the Keto-CTA scans, by analysis software
Cleerly (original, retracted paper)18.8 mm³
QAngio (re-analysis)5.6 mm³
HeartFlow (re-analysis)5.5 mm³
The original Cleerly-based paper was retracted and the 200 scans were re-analyzed. Nature-CT, a comparison group read with Cleerly, had a median of 4.9 mm³. Source: 57
Show data
mm³
Cleerly (original, retracted paper)18.8 mm³
QAngio (re-analysis)5.6 mm³
HeartFlow (re-analysis)5.5 mm³

Radiation and cost

Louis says CAC scans use much less radiation than CT angiography but predict risk less accurately. He cautions about a JAMA Internal Medicine projection of cancers from CT imaging because it is observational and subject to confounding40. Gokhan lists cost and radiation as downsides of CCTA2.

Sex differences

A Danish cohort of 10,003 asymptomatic adults over 40 found plaque less frequent in women at every age (6% versus 20% at ages 40 to 44). Obstructive disease carried a 4.1-fold higher heart attack risk in women versus 12-fold in men over about six years, although the sex interaction was not statistically significant41.

Exercise and plaque

Louis highlighted the Master@Heart analysis linking higher wearable-measured training load to more coronary atherosclerosis on CCTA in middle-aged and older athletes. He stresses this concerns extremes of intensity plus volume, not typical exercisers42.

What this means for you

The group's posts do not provide a formal guideline for who should get a CCTA, but they suggest these themes. Discuss each with your doctor.

  • Chest pain. The best randomized evidence in the group, SCOT-HEART, is in people with stable chest pain2.
  • Known plaque. The ACC guidance as summarized supports plaque analysis for people who already have plaque on a scan, with rescans at two to five year intervals at minimum1.
  • Zero calcium but concern remains. Given the Danish and REACT findings, a zero CAC does not rule out soft plaque, particularly in younger people312.
  • Very high LDL on a keto diet. Budoff recommends CT angiograms for his ketogenic patients and a statin, low-dose aspirin and tight blood pressure control for those with significant plaque43.
  • Radiation-free alternatives. One member who is a keto practitioner with high Lp(a) chose a carotid intima-media thickness test first and planned CCTA later44.
  • Motivation. Louis shared JAMA findings that CCTA, compared with risk scoring, was linked to modest improvements in lifestyle, acceptance of preventive therapy and risk factor control45.
  • Read results carefully. Ask whether total plaque, soft plaque and calcified plaque are reported separately, and which software was used.

Frequently asked questions

What does CCTA show that CAC does not?

CAC reflects calcified plaque only, while quantitative analysis of a CCTA characterizes all plaque types, including soft low-density plaque1.

Does a normal CCTA mean I have no plaque?

Not necessarily. Louis notes that contrast CT mainly shows plaque that has grown enough to affect the lumen, so early wall plaque can be missed8.

Why did my soft plaque shrink but my total plaque stay flat?

Calcified plaque can rise as soft plaque hardens. In the evolocumab study total plaque was unchanged while soft plaque fell and calcified plaque rose15. In FLOWPROMOTE calcified plaque rose but total plaque still fell20.

How often should I rescan?

The ACC guidance as summarized in the group says two to five years at minimum1.

Does SCOT-HEART prove scanning prevents heart attacks in everyone?

No. It enrolled people with stable chest pain, and the benefit appears to come from better targeting of aspirin and statins2.

Are numbers from different studies directly comparable?

Only with caution: different software gave very different results for the same scans, and units (mm3 versus uL) and baseline risk vary715.

The evidence behind this summary37 studies · 17 trials · 10 observational

The 45 group posts cited above discuss 37 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Randomized trials 17Observational studies 10Reviews & guidelines 2Other sources 8

Strongest evidence discussed

All 37 studies and sources
Sources from the group (45)
  1. ACC guidance backs AI plaque analysis on CT angiography to guide and track treatment Louis Nervegna · Jun 01, 2026 · Facebook
  2. SCOT-HEART: CT angiography cut 5-year coronary death or MI risk 41% in chest pain patients Gokhan Can · Jan 03, 2026 · Facebook
  3. A zero CAC score does not rule out blockages: 54% of 23,759 symptomatic patients had CAC 0 Louis Nervegna · Jan 01, 2025 · Facebook
  4. A zero CAC does not rule out plaque in symptomatic patients; 54% had CAC 0 in Denmark Louis Nervegna · Dec 22, 2023 · Facebook
  5. Keto-CTA hyper-responders progressed soft plaque 3.8x faster than Nature-CT controls Louis Nervegna · Apr 18, 2025 · Facebook
  6. DISCO-CT: DASH diet plus statins reversed soft plaque by about 40 mm3 in a year Louis Nervegna · Aug 18, 2025 · Facebook
  7. Keto-CTA vs DISCO-CT: plaque progression on keto in LMHR versus DASH diet plus statins Louis Nervegna · Oct 25, 2026 · Facebook
  8. A CT angiogram shows the lumen, so it can miss early plaque inside the artery wall Louis Nervegna · Apr 07, 2025 · Facebook
  9. Calcified plaque is a marker, the goal should be reversing soft plaque Louis Nervegna · Aug 16, 2025 · Facebook
  10. The four stages of coronary artery disease, from soft plaque to ischemia Gokhan Can · Jul 27, 2024 · Facebook
  11. PARADIGM: statins shift coronary plaque toward denser, lower-risk calcified lesions Louis Nervegna · Dec 02, 2025 · Facebook
  12. REACT: silent atherosclerosis found in 57% of 16,808 adults, 7-9% of 18-29-year-olds Louis Nervegna · Sep 26, 2026 · Facebook
  13. REACT in NEJM: 57% of adults have atherosclerosis and age is the biggest risk factor Louis Nervegna · Aug 30, 2026 · Facebook
  14. Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs Louis Nervegna · Aug 12, 2025 · Facebook
  15. Repatha for 18 months reduced non-calcified plaque on CT angiography in a 47-patient study Louis Nervegna · Mar 02, 2026 · Facebook
  16. CT angiography plaque burden often predicts events better than stenosis severity Louis Nervegna · Jun 09, 2026 · Facebook
  17. CaRi-Heart AI on CT angiograms measures coronary inflammation missed by hs-CRP Louis Nervegna · Sep 18, 2026 · Facebook
  18. Six RCTs show statins reverse total plaque volume by 5% to 17% Louis Nervegna · Aug 25, 2026 · Facebook
  19. Six randomized trials show statins reduce total plaque volume 5-17% from baseline Louis Nervegna · Mar 02, 2026 · Facebook
  20. FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months Louis Nervegna · Oct 31, 2026 · Facebook
  21. FLOWPROMOTE: combination therapy shrank soft plaque 28% vs 20% with LDL near 42 vs 70 Louis Nervegna · Oct 31, 2026 · Facebook
  22. Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30 Louis Nervegna · Nov 13, 2026 · Facebook
  23. Keto-CTA plaque growth matched diabetics' and far exceeded high-risk statin-treated groups Louis Nervegna · Apr 16, 2025 · Facebook
  24. DISCO-CT: DASH diet plus statins reversed ~40 mm3 of soft plaque in a year on CT Louis Nervegna · Aug 12, 2026 · Facebook
  25. Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff) Louis Nervegna · May 11, 2025 · Facebook
  26. Aged garlic extract reduced high-risk soft plaque in a small CT-angiography RCT Louis Nervegna · Dec 27, 2025 · Facebook
  27. Testosterone therapy accelerated soft plaque growth by 41 mm3 in older men in a 2017 RCT Louis Nervegna · Aug 13, 2025 · Facebook
  28. Olezarsen cut triglycerides 64% but did not change plaque in ESSENCE-TIMI 73b imaging Louis Nervegna · Mar 31, 2026 · Facebook
  29. Group member reports 'widowmaker' soft plaque regression on 6 g/day EPA, citing EVAPORATE Louis Nervegna · May 04, 2026 · Facebook
  30. A normal coronary CTA can still miss early wall plaque that has not narrowed the lumen Louis Nervegna · Jul 25, 2024 · Facebook
  31. Ornish trial's 'plaque reversal' may be x-ray angiography measurement error Louis Nervegna · Dec 05, 2025 · Facebook
  32. A normal angiogram can hide large plaque burden because of Glagov remodeling Louis Nervegna · Dec 13, 2025 · Facebook
  33. Keto-CTA vs Nature-CT: same scanners and software, 3.8x faster plaque progression on keto Louis Nervegna · Aug 21, 2025 · Facebook
  34. KETO-CTA's preregistered primary outcome was missing from the paper, says Dr Albert Gokhan Can · Apr 12, 2025 · Facebook
  35. Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque Louis Nervegna · Apr 21, 2025 · Facebook
  36. Nicola Guess: Keto-CTA plaque rose ~20 mm3 in 1 year vs ~13 mm3 over 3 years in PARADIGM Louis Nervegna · Apr 12, 2025 · Facebook
  37. Keto-CTA reanalysis: plaque progression still no better than the standard American diet Louis Nervegna · Sep 06, 2025 · Facebook
  38. Keto-CTA reanalysis with new software: plaque progression matches the standard diet group Louis Nervegna · Sep 05, 2025 · Facebook
  39. Independent reanalysis accuses the Keto-CTA study of statistical violations Louis Nervegna · Mar 15, 2026 · Facebook
  40. CT scan cancer risk must be weighed against the benefit of tracking plaque Louis Nervegna · Aug 21, 2025 · Facebook
  41. Same CT plaque, lower MI risk in women than men in a 10,003-person Danish cohort Louis Nervegna · Aug 30, 2026 · Facebook
  42. Master@Heart: higher wearable-measured training load linked to more coronary plaque Louis Nervegna · Mar 06, 2026 · Facebook
  43. Budoff recommends statins, aspirin and BP control for keto dieters with CT-detected plaque Louis Nervegna · Apr 14, 2025 · Facebook
  44. Staying keto while still tracking ApoB and plaque markers (shared from Dominic D'Agostino) Gokhan Can · Aug 30, 2025 · Facebook
  45. Coronary CT angiography modestly improved lifestyle and therapy uptake vs risk scoring Louis Nervegna · Jun 22, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary